|
Coagulation Product Line
Octapharma’s first product was, the first solvent detergent inactivated FVIII concentrate – used in the treatment of haemophilia A . Providing safe and effective therapy for coagulation disorders remains one of the core activities of the company. Octapharma engages top clinical researchers in our clinical studies, regularly contributes new clinical information, and establishes partnerships with patient centered organizations such as the WFH and other national haemophilia societies.
Click here to review general information about the indiciations for the Coagulation Product Line.
 |
|
|
wilate® - new generation, high purity, VWF/FVIII-concentrate with two independent virus inactivation steps (PermaHeat (100°C for 120 min) and S/D treatment) for the treatment of von Willebrand Disease (VWD) and haemophilia A. Available in 450 IU and 900 IU vials.
SPC below is valid in these countries:
RMS: DE. CMS: AT, BE, DK, FI, LU, NO, PT, SE.
|
|
|
|
|
|
|
|
|
|
 |
|
|
nanotiv® - high purity SD treated and nano-filtered Factor IX concentrate for the prophylaxis and treatment of Haemophilia B. Available in 500 IU and 1000 IU vials.
SPC below is valid in these countries:
RMS: SE. CMS: DK, LU, NL, NO, PT, ES.
|
|
|
|
|
|
|
|
|
|
 |
|
|
octanate® - double virus-inactivated, high purity Factor VIII – von Willebrand Factor (VWF) concentrate for prophylaxis and treatment of bleeding in haemophilia A. Available in 250 IU, 500 IU and 1000 IU presentations. (Sold in Brazil under the registered name Octavi SDOptimum® and in Portugal as Emoclot DI).
SPC below is valid in these countries:
RMS: AT. CMS: BE, CY, DK, FI, EL, IE, LU, NL, UK, FR, LV, LT, ES, SE.
|
|
|
|
|
|
|
|
|
|
 |
|
|
octanine® F - SD virus-inactivated, nano-filtered Factor IX concentrate for the prophylaxis and treatment of bleeding in haemophilia B. Available in 250 IU, 500 IU and 1000 IU presentations.
SPC below is valid in these countries:
RMS: DE. CMS: BE, FI, FR, LU, UK.
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
Octapharma will sponsor two satellite symposia at the upcoming ISBT Congress, June 7 - 12, 2008 in Macau SAR, China
May 27, 2008
Octapharma at WFH Congress, June 1 - 5, 2008, Istanbul, Turkey
May 24, 2008
Octapharma acquisition of a plasma fractionation plant in Springe, Germany from German Red Cross organizations
May 8, 2008
|
|
|
|
